BCL6 (BCL6 transcription repressor; HGNC:1001, NCBI Gene 604) is the gene on chromosome 3q27.3 encoding the BTB/POZ zinc-finger repressor of the germinal-center reaction — licensing somatic hypermutation and class-switching by silencing the DNA-damage checkpoints (including p53) that would stop the mutating B cell; its translocations (3q27) causing diffuse-large-B-cell and follicular lymphomas; the protein page holding the mechanism.
Approved Symbol
BCL6 (HGNC:1001)
Chromosomal Locus
3q27.3
Encoded Product
BCL6 — a 95-kDa BTB/POZ zinc-finger repressor (706 aa)
Genomic organization: Ten exons; the N-terminal BTB domain (the corepressor-docking dimer) and six zinc fingers; the 3q27 translocations juxtaposing heterologous promoters (the immunoglobulin loci) that decouple BCL6 from its normal downregulation.
Expression: Germinal-center B cells (and T-follicular-helper cells); IRF4/BLIMP1's plasma-cell program the differentiation endpoint that normally silences it.
Lymphoma biology depth: BCL6's translocation partners (the Ig loci, BCL6's own promoter region's rearrangement variety) and the AID-machinery origin of the breaks — the germinal-center program leaving its own mutation signature.
Targeting depth: The BTB-groove peptide scaffolds (the Melnick programs) and the newer degraders — revoking the germinal-center license the tumor still depends on; the T-cell lymphoma contexts extending the file.
Molecular Function & Pathways
Licensing program: BCL6's repression of TP53, ATR/CHEK1, p21, and ARF tolerating the AID-driven breaks of hypermutation — the two-week window's mutagenic license; the protein page for the full program and acetylation off-switch.
Oncogenic arrest: The translocations holding the license open — the B cell stuck in the cycling centroblast state (the lymphoma); MYC co-translocation (double-hit) the worst combination.
Clinical & Therapeutic Significance
Clinical genetics: BCL6 rearrangement a routine DLBCL/follicular marker (the cell-of-origin classification's components); the BTB-inhibitor and degrader programs (the RX5 successors in trial) revoking the tumor's license.
Assay note: BCL6 protein immunostaining the diagnostic standby; the T-follicular-helper flow panel's canonical marker.